NR 546 Advanced Pharmacology Psychopharmacology for the
PMHNP Week 4 Midterm Exam 2026/2027 - Questions and
Answers 100% Verified Detailed Rationales - Pass Guaranteed -
A+ Graded
This midterm examination assesses graduate-level mastery of psychopharmacologic principles central to PMHNP
practice, including neurotransmitter systems, pharmacokinetics and pharmacodynamics, major psychotropic drug
classes, FDA indications and black box warnings, monitoring parameters, special populations, and
evidence-based prescribing and deprescribing standards. Items emphasize clinical application, safety, and current
2026 guideline concordance. It contains 98 multiple-choice questions, each with four distractors and a fully
worked rationale that explains why the keyed answer is correct. Questions are organized into clearly labelled
sections that mirror the major content areas of the course. Targeted learning outcomes include: Apply
pharmacokinetic and pharmacodynamic principles to individualize psychotropic therapy and interpret drug
interactions.; Select, monitor, and adjust psychotropic agents based on FDA labeling, black box warnings, and
evidence-based guidelines.; Integrate special-population, legal, and deprescribing considerations into safe
psychiatric prescribing for the PMHNP role.. Every item has been reviewed for clinical accuracy, current
guidelines, and clarity so that students can study with confidence and self-correct as they work through the bank.
Use it as a high-yield review immediately before the exam, or as a structured practice tool during the unit - the
rationales double as concise teaching notes. The recommended writing time is 2 hours, with a passing score of
80%. Aligned with Aligned with ANCC PMHNP test content outline, AANP certification blueprint, APA practice
Section 1: General (Questions 1-98)
1 Which cytochrome pathway most determines clozapine's dose-dependent toxicity
risk during fluvoxamine co-administration?
A) CYP3A4
B) CYP1A2
C) CYP2D6
D) CYP2C19
Answer: B
Rationale: Clozapine is primarily metabolized by CYP1A2; fluvoxamine is a potent
CYP1A2 inhibitor and can raise clozapine levels, increasing toxicity risk. CYP3A4,
CYP2D6, and CYP2C19 are not the principal pathways for clozapine and are less
clinically decisive here.
2 Which lab parameter must be monitored weekly during the first six months of
clozapine therapy?
A) Serum lithium level
B) Absolute neutrophil count
C) Thyroid-stimulating hormone
D) Prothrombin time
,Answer: B
Rationale: Clozapine carries a black box warning for severe neutropenia, requiring
weekly absolute neutrophil count monitoring for six months, then biweekly, then
monthly. Lithium levels, TSH, and PT are not the mandated safety monitoring for
clozapine.
3 Which medication requires monitoring for metabolic syndrome,
hyperprolactinemia, and QT prolongation simultaneously?
A) Sertraline
B) Risperidone
C) Lamotrigine
D) Buspirone
Answer: B
Rationale: Risperidone is an atypical antipsychotic associated with metabolic effects,
prolactin elevation, and QT prolongation, warranting combined monitoring.
Sertraline, lamotrigine, and buspirone do not carry this same triad of risks.
4 Which SSRI is safest in pregnancy and lactation due to the most extensive safety
data?
A) Paroxetine
B) Sertraline
C) Fluvoxamine
D) Citalopram
Answer: B
Rationale: Sertraline has the largest body of safety data in pregnancy and lactation
and is generally preferred. Paroxetine is associated with cardiac malformations,
while fluvoxamine and citalopram have less robust reproductive safety data.
5 Which statement best reflects the 2025 APA guideline for treatment-resistant
depression augmentation?
A) Always start with MAOI augmentation
B) Atypical antipsychotic augmentation is evidence-based
C) Benzodiazepine augmentation is first-line
D) Stimulant augmentation is contraindicated
Answer: B
Rationale: The APA guideline supports atypical antipsychotic augmentation for
treatment-resistant depression based on strong evidence. MAOIs are not first-line,
benzodiazepines are not used for augmentation, and stimulants are not absolutely
,contraindicated but are not the guideline-preferred strategy.
6 Which pharmacodynamic principle explains why benzodiazepines and opioids
together increase respiratory depression risk?
A) Additive CNS depression
B) Enzyme induction
C) Renal clearance competition
D) Protein binding displacement
Answer: A
Rationale: Both drug classes enhance GABAergic or opioidergic inhibition,
producing additive CNS and respiratory depression. Enzyme induction, renal
competition, and protein binding displacement do not explain this synergistic effect.
7 Which medication requires a black box warning for suicidal ideation in patients
under 25 years?
A) Bupropion
B) Lithium
C) Lorazepam
D) Diphenhydramine
Answer: A
Rationale: Bupropion, like all antidepressants, carries a black box warning for
increased suicidal ideation in patients younger than 25. Lithium, lorazepam, and
diphenhydramine do not carry this specific warning.
8 Which monitoring parameter is essential before and during lithium therapy to
prevent toxicity?
A) Serum creatinine and thyroid function
B) Complete blood count
C) Liver function tests
D) Urine drug screen
Answer: A
Rationale: Lithium requires baseline and periodic renal and thyroid function
monitoring because it can cause nephrogenic diabetes insipidus and hypothyroidism.
CBC, LFTs, and urine drug screens are not the primary monitoring parameters for
lithium.
9 Which deprescribing strategy is recommended for long-term benzodiazepine use
in older adults?
, A) Abrupt discontinuation
B) Gradual taper with CBT
C) Switch to another benzodiazepine
D) Add an antipsychotic
Answer: B
Rationale: Guidelines recommend gradual tapering combined with cognitive
behavioral therapy to manage withdrawal and underlying symptoms. Abrupt
discontinuation risks withdrawal seizures, switching does not address dependence,
and adding an antipsychotic increases risk without benefit.
10 Blockade of which receptor best explains quetiapine's low extrapyramidal
symptom risk at therapeutic doses?
A) D2 receptor partial agonism at mesolimbic terminals
B) Fast dissociation from the D2 receptor combined with 5-HT2A antagonism
C) Selective D4 receptor antagonism in the striatum
D) Presynaptic dopamine depletion via VMAT2 inhibition
Answer: B
Rationale: Quetiapine binds D2 with low affinity and dissociates rapidly ('fast-off'
kinetics) while blocking 5-HT2A, which disinhibits striatal dopamine and reduces
EPS. Partial D2 agonism describes aripiprazole, D4 selectivity is not clinically
established, and VMAT2 inhibition describes tetrabenazine, not quetiapine.
11 Which CYP-mediated interaction most accurately predicts toxic clozapine levels
when fluvoxamine is co-prescribed?
A) Fluvoxamine inhibits CYP3A4, reducing clozapine clearance
B) Fluvoxamine induces CYP1A2, accelerating norclozapine formation
C) Fluvoxamine potently inhibits CYP1A2, the enzyme clearing clozapine
D) Fluvoxamine inhibits CYP2D6, shunting clozapine to CYP3A4
Answer: C
Rationale: Clozapine is primarily metabolized by CYP1A2, and fluvoxamine is a
potent CYP1A2 inhibitor, so co-administration markedly raises clozapine levels and
toxicity risk. CYP3A4, CYP2D6, and induction mechanisms do not explain this
specific interaction; fluvoxamine inhibits rather than induces CYP1A2.
12 Which lab parameter must be monitored most rigorously during lithium initiation
and titration?
A) Serum sodium and fasting glucose
B) Renal function, thyroid function, and lithium level
PMHNP Week 4 Midterm Exam 2026/2027 - Questions and
Answers 100% Verified Detailed Rationales - Pass Guaranteed -
A+ Graded
This midterm examination assesses graduate-level mastery of psychopharmacologic principles central to PMHNP
practice, including neurotransmitter systems, pharmacokinetics and pharmacodynamics, major psychotropic drug
classes, FDA indications and black box warnings, monitoring parameters, special populations, and
evidence-based prescribing and deprescribing standards. Items emphasize clinical application, safety, and current
2026 guideline concordance. It contains 98 multiple-choice questions, each with four distractors and a fully
worked rationale that explains why the keyed answer is correct. Questions are organized into clearly labelled
sections that mirror the major content areas of the course. Targeted learning outcomes include: Apply
pharmacokinetic and pharmacodynamic principles to individualize psychotropic therapy and interpret drug
interactions.; Select, monitor, and adjust psychotropic agents based on FDA labeling, black box warnings, and
evidence-based guidelines.; Integrate special-population, legal, and deprescribing considerations into safe
psychiatric prescribing for the PMHNP role.. Every item has been reviewed for clinical accuracy, current
guidelines, and clarity so that students can study with confidence and self-correct as they work through the bank.
Use it as a high-yield review immediately before the exam, or as a structured practice tool during the unit - the
rationales double as concise teaching notes. The recommended writing time is 2 hours, with a passing score of
80%. Aligned with Aligned with ANCC PMHNP test content outline, AANP certification blueprint, APA practice
Section 1: General (Questions 1-98)
1 Which cytochrome pathway most determines clozapine's dose-dependent toxicity
risk during fluvoxamine co-administration?
A) CYP3A4
B) CYP1A2
C) CYP2D6
D) CYP2C19
Answer: B
Rationale: Clozapine is primarily metabolized by CYP1A2; fluvoxamine is a potent
CYP1A2 inhibitor and can raise clozapine levels, increasing toxicity risk. CYP3A4,
CYP2D6, and CYP2C19 are not the principal pathways for clozapine and are less
clinically decisive here.
2 Which lab parameter must be monitored weekly during the first six months of
clozapine therapy?
A) Serum lithium level
B) Absolute neutrophil count
C) Thyroid-stimulating hormone
D) Prothrombin time
,Answer: B
Rationale: Clozapine carries a black box warning for severe neutropenia, requiring
weekly absolute neutrophil count monitoring for six months, then biweekly, then
monthly. Lithium levels, TSH, and PT are not the mandated safety monitoring for
clozapine.
3 Which medication requires monitoring for metabolic syndrome,
hyperprolactinemia, and QT prolongation simultaneously?
A) Sertraline
B) Risperidone
C) Lamotrigine
D) Buspirone
Answer: B
Rationale: Risperidone is an atypical antipsychotic associated with metabolic effects,
prolactin elevation, and QT prolongation, warranting combined monitoring.
Sertraline, lamotrigine, and buspirone do not carry this same triad of risks.
4 Which SSRI is safest in pregnancy and lactation due to the most extensive safety
data?
A) Paroxetine
B) Sertraline
C) Fluvoxamine
D) Citalopram
Answer: B
Rationale: Sertraline has the largest body of safety data in pregnancy and lactation
and is generally preferred. Paroxetine is associated with cardiac malformations,
while fluvoxamine and citalopram have less robust reproductive safety data.
5 Which statement best reflects the 2025 APA guideline for treatment-resistant
depression augmentation?
A) Always start with MAOI augmentation
B) Atypical antipsychotic augmentation is evidence-based
C) Benzodiazepine augmentation is first-line
D) Stimulant augmentation is contraindicated
Answer: B
Rationale: The APA guideline supports atypical antipsychotic augmentation for
treatment-resistant depression based on strong evidence. MAOIs are not first-line,
benzodiazepines are not used for augmentation, and stimulants are not absolutely
,contraindicated but are not the guideline-preferred strategy.
6 Which pharmacodynamic principle explains why benzodiazepines and opioids
together increase respiratory depression risk?
A) Additive CNS depression
B) Enzyme induction
C) Renal clearance competition
D) Protein binding displacement
Answer: A
Rationale: Both drug classes enhance GABAergic or opioidergic inhibition,
producing additive CNS and respiratory depression. Enzyme induction, renal
competition, and protein binding displacement do not explain this synergistic effect.
7 Which medication requires a black box warning for suicidal ideation in patients
under 25 years?
A) Bupropion
B) Lithium
C) Lorazepam
D) Diphenhydramine
Answer: A
Rationale: Bupropion, like all antidepressants, carries a black box warning for
increased suicidal ideation in patients younger than 25. Lithium, lorazepam, and
diphenhydramine do not carry this specific warning.
8 Which monitoring parameter is essential before and during lithium therapy to
prevent toxicity?
A) Serum creatinine and thyroid function
B) Complete blood count
C) Liver function tests
D) Urine drug screen
Answer: A
Rationale: Lithium requires baseline and periodic renal and thyroid function
monitoring because it can cause nephrogenic diabetes insipidus and hypothyroidism.
CBC, LFTs, and urine drug screens are not the primary monitoring parameters for
lithium.
9 Which deprescribing strategy is recommended for long-term benzodiazepine use
in older adults?
, A) Abrupt discontinuation
B) Gradual taper with CBT
C) Switch to another benzodiazepine
D) Add an antipsychotic
Answer: B
Rationale: Guidelines recommend gradual tapering combined with cognitive
behavioral therapy to manage withdrawal and underlying symptoms. Abrupt
discontinuation risks withdrawal seizures, switching does not address dependence,
and adding an antipsychotic increases risk without benefit.
10 Blockade of which receptor best explains quetiapine's low extrapyramidal
symptom risk at therapeutic doses?
A) D2 receptor partial agonism at mesolimbic terminals
B) Fast dissociation from the D2 receptor combined with 5-HT2A antagonism
C) Selective D4 receptor antagonism in the striatum
D) Presynaptic dopamine depletion via VMAT2 inhibition
Answer: B
Rationale: Quetiapine binds D2 with low affinity and dissociates rapidly ('fast-off'
kinetics) while blocking 5-HT2A, which disinhibits striatal dopamine and reduces
EPS. Partial D2 agonism describes aripiprazole, D4 selectivity is not clinically
established, and VMAT2 inhibition describes tetrabenazine, not quetiapine.
11 Which CYP-mediated interaction most accurately predicts toxic clozapine levels
when fluvoxamine is co-prescribed?
A) Fluvoxamine inhibits CYP3A4, reducing clozapine clearance
B) Fluvoxamine induces CYP1A2, accelerating norclozapine formation
C) Fluvoxamine potently inhibits CYP1A2, the enzyme clearing clozapine
D) Fluvoxamine inhibits CYP2D6, shunting clozapine to CYP3A4
Answer: C
Rationale: Clozapine is primarily metabolized by CYP1A2, and fluvoxamine is a
potent CYP1A2 inhibitor, so co-administration markedly raises clozapine levels and
toxicity risk. CYP3A4, CYP2D6, and induction mechanisms do not explain this
specific interaction; fluvoxamine inhibits rather than induces CYP1A2.
12 Which lab parameter must be monitored most rigorously during lithium initiation
and titration?
A) Serum sodium and fasting glucose
B) Renal function, thyroid function, and lithium level
